When Therapy Doesn’t Work: Why People Turn to Psychedelic-Assisted Therapy

There is a specific kind of exhaustion that comes from doing everything right. You found a therapist. You showed up weekly. You took the medication as prescribed, waited the six to eight weeks you were told to wait, tolerated the side effects, and then switched when it did not work. You tried the second one. Maybe the third. And you are still not well.

This is the situation that brings most people to psychedelic-assisted therapy. Not curiosity, and not a search for a peak experience. When therapy doesn’t work and the medications have not helped either, the question stops being philosophical and becomes practical: what else is there, and does any of it actually hold up?

This post looks at why conventional treatment fails as often as it does, what the research on psychedelic-assisted therapy actually supports for people in that position, and how to think clearly about whether it makes sense for you.

How Often Does Standard Treatment Actually Fail?

More often than most people are told.

The largest real-world study of antidepressant treatment ever conducted, the NIMH-funded STAR*D trial, followed 3,671 adults with major depression through up to four sequential treatment attempts. The results are worth sitting with. Roughly a third of participants reached remission on the first medication. Among those who did not and moved to a second, the remission rate fell. By the third attempt it was in the mid-teens, and by the fourth it was around 13 percent.

The pattern matters more than any single number. Each failed medication trial makes the next one less likely to work. This is not a character flaw or a sign that you did not try hard enough. It is a documented feature of how depression responds to serotonergic medication, and it is why clinicians now use two failed antidepressant trials as the working definition of treatment-resistant depression.

The picture in PTSD is similar. First-line treatments, including trauma-focused cognitive behavioral therapy and prolonged exposure, help many people. But dropout rates in trauma therapy are high, and a meaningful share of those who complete a full course still meet diagnostic criteria afterward. For complex trauma that began in childhood, the results are less consistent still.

None of this means conventional treatment is worthless. It works for the majority. But if you are in the minority for whom it has not worked, you deserve an honest accounting of where that leaves you rather than a suggestion to try a fourth SSRI.

What Draws People Toward Psychedelic-Assisted Therapy?

Three things, mostly.

The first is mechanism. Conventional antidepressants work primarily by adjusting serotonin availability, and they are taken daily, often indefinitely. Psychedelic compounds appear to work differently. Psilocybin, once converted in the body to psilocin, activates receptors concentrated in the parts of the brain most involved in mood and self-reflection. What follows is a temporary window of heightened neuroplasticity, meaning the brain becomes unusually capable of forming new connections and loosening entrenched patterns. Ketamine reaches a similar state through the glutamate system rather than the serotonin system. For someone who has spent years managing symptoms, the possibility of changing the underlying pattern rather than suppressing its expression is genuinely different.

The second is durability. Standard antidepressants stop working when you stop taking them. Several psychedelic trials have measured effects that persist for weeks or months after a single supervised session, which is a categorically different treatment model.

The third is that people have run out of alternatives. Desperation is a real driver here, and it deserves to be handled with care rather than exploited. Someone arriving at this decision after five failed treatments is more vulnerable to overpromising, not less.

What Does the Evidence Actually Show for Treatment-Resistant Cases?

This is where precision matters. The research is uneven across compounds and conditions, and treating it as a single body of evidence does readers a disservice.

Psilocybin for treatment-resistant depression

This is the strongest case. The COMPASS Pathways Phase 2b trial, published in the New England Journal of Medicine in 2022, enrolled 233 people with treatment-resistant depression across 22 sites in 10 countries. Participants had failed between two and four prior treatments. A single 25mg dose of synthetic psilocybin (roughly equivalent to 3 to 4 grams of dried Psilocybe cubensis, though clinical trials use pharmaceutical-grade material with precise dosing) produced a statistically and clinically significant reduction in depression symptoms at three weeks compared to a 1mg control. Around 29 percent of the 25mg group met criteria for remission at week 3, and 37 percent met criteria for response.

Phase 3 trials have since reported positive results, and the sponsor has indicated it is preparing an FDA submission. What we can say with confidence is that in a population where standard treatment had already failed multiple times, a single supervised session moved roughly a third of people into remission. What we cannot say is that this works for everyone, or that it is permanent.

Ketamine and esketamine

Ketamine is the only option in this category that is legally accessible nationwide right now. Esketamine, the nasal spray marketed as Spravato, was approved by the FDA in January 2025 as the first standalone treatment for adults with treatment-resistant depression, meaning it no longer needs to be paired with a daily oral antidepressant. In the pivotal trial supporting that approval, about 22.5 percent of participants reached remission by week four, compared to 7.6 percent on placebo.

Those are real numbers for a hard population, and the effect can appear within 24 hours rather than six weeks. The trade-off is durability. Ketamine’s effects typically fade without repeated sessions, which makes it a different proposition from a single-session model. It also carries genuine abuse potential and requires clinical supervision.

MDMA for PTSD

The Phase 3 data from the MAPS-sponsored trials was among the most promising in psychiatric research. The FDA nonetheless declined to approve MDMA-assisted therapy in August 2024, citing concerns about functional unblinding, durability data, and trial conduct. As of mid-2026, that decision stands. This matters for anyone weighing options: the evidence and the legal availability are two separate questions, and a compound can look strong in trials while remaining unavailable.

Everything else

LSD, ayahuasca, ibogaine, and 5-MeO-DMT all have early signals in one condition or another. The research is genuinely early, mostly small, and in some cases limited to observational or survey data. Ibogaine in particular carries documented cardiac risk that has caused deaths. Treat any claim of strong evidence in these areas with skepticism.

Is Psychedelic Therapy a Last Resort?

The framing is understandable but not quite right, and it introduces two distortions.

The first distortion is that a last resort implies certainty. It suggests the thing you turn to when nothing else works must be the thing that works. Psychedelic-assisted therapy does not carry that guarantee. In the COMPASS trial, a majority of participants in the 25mg group did not reach remission. That is still a meaningful result in a treatment-resistant population, but it is not a cure.

The second distortion is sequencing. Treating this as the option of absolute final resort implies you should exhaust every conventional avenue first, including medications with declining odds of success. There is a reasonable argument that for some people, particularly those who have already had two clear treatment failures, continuing to cycle through additional antidepressants is not a neutral choice. It costs time, and it delays other options.

The better framing is that psychedelic-assisted therapy is one option among several for a specific clinical situation, with a specific evidence base, specific risks, and specific access constraints. It should be evaluated the way you would evaluate any other significant medical decision.

Who Should Not Pursue This?

Some people should stop here, and the reasons are not negotiable.

A personal or immediate family history of psychosis or bipolar I disorder is a firm contraindication for classic psychedelics. Certain cardiac conditions rule out several compounds, and ibogaine in particular. Active suicidal ideation requires stabilization before anything else is considered.

Medication interactions are the issue that trips up the most people in this exact position, because the people considering psychedelic therapy are, almost by definition, people currently taking psychiatric medication. SSRIs can blunt psilocybin’s effects, and tapering carries its own risks that must be managed by a prescribing physician rather than improvised. Lithium combined with classic psychedelics has been associated with seizures. This is covered in more depth in our overview of medical contraindications and who should pause before pursuing psychedelic therapy, and it is worth reading before you go further.

What to Do If You’re at This Point

Start with an honest inventory. How many medications have you actually tried, at adequate doses, for an adequate duration? Two failed trials is the clinical threshold for treatment resistance, but a medication abandoned after ten days because of nausea is not a failed trial. Being precise here changes what options are appropriate.

Then look at what is legally available where you live. Ketamine therapy is accessible in every state and is the only professionally supervised option that is unambiguously legal nationwide. Oregon and Colorado have regulated psilocybin frameworks that do not require residency. Everywhere else, psilocybin remains illegal regardless of local decriminalization ordinances, and a state-by-state breakdown is worth reviewing before you make plans.

Talk to your prescribing physician before you do anything else, particularly if you are on an SSRI. This conversation is more manageable than most people expect, and going into it prepared makes a difference.

Finally, be rigorous about who you work with. The people most likely to be harmed in this space are the ones who arrive exhausted, out of options, and willing to accept whatever is offered. That vulnerability is exactly what a professional structure exists to protect. A qualified guide screens you properly, coordinates with your medical providers, prepares you before the session, holds the session safely, and supports the integration work afterward. Anyone who skips those steps is not offering therapy. Our guide to vetting a guide’s credentials covers the questions that actually separate professionals from opportunists.